Abstract
Managing medication use is one of the most challenging aspects of caring for older adults. This is because the older adult has added variability in their pharmacokinetics, pharmacodynamics, and response to pharmacologic agents beyond the typical variability seen from one person to another. While oral absorption is slowed, for chronic medications no patient concerns occur; however, transdermal absorption may vary considerably in older adults. Distribution varies based upon the hydrophilic and lipophilic drug properties. Metabolism is often slowed, causing drug accumulation in the body. Likewise excretion is usually reduced, further impairing elimination from the body. Although it is well recognized that older adults have altered pharmacokinetic parameters as compared to young, healthy adults, seldom are pharmacokinetic data obtained in this population prior to drug release. Clinical trials for new agents recruit some older adults with co-morbidity; less than 4% of trials included pharmacokinetic evaluations in this group. The lack of data in the geriatric population requires extrapolation of information understood about the group as a whole when starting a new medication followed by cautious and careful monitoring for therapeutic and adverse effects. Beyond the pharmacokinetic issues are concerns with drug exposure. Polypharmacy creates an increased potential for drug-drug, drug-food, and drug-disease interactions. Rational deprescribing requires a stepwise approach to identifying agents that should be discontinued and removing them from the drug regimen in a way as to not create withdrawal or rebound symptoms. This chapter will describe the pharmacokinetic and pharmacodynamics variability usually encountered in older adults as a foundation for consideration in the various gastrointestinal illnesses and their treatment. Medications which may cause or are used in common gastrointestinal illnesses seen in older adults are reviewed.
References
Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med. 2005;353(4):432–3.
Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6:735–54. https://doi.org/10.1007/s13346-016-0339-2.
Albuhewa AY, Williams DB, Upton RN, Foster DJR. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 2017;112:234–48. https://doi.org/10.1016/j.ejpb.2016.11.034.
Ali MA, Lacy BE. Abdominal complaints and gastrointestinal disorders. In: Landefeld CS, Palmer RM, Johnson MA, et al., editors. Current geritric diagnosis and treatment. New York: McGraw-Hill; 2004. p. 220–38.
American Geriatrics Society 2019 Beers Criteria® Update Expert Panel. 2019 updated Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94. https://doi.org/10.1111/jgs.13702.
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society. J Am Geriatr Soc. 2012;60:1957–68. https://doi.org/10.1111/j.1532-5415.2012.04187.x.
Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106(Suppl):1559S–66S. https://doi.org/10.3945/ajcn.117.155804.
Anti M, Pignataro G, Armuzzi A, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepato-Gastroenterology. 1998;45(21):727–32.
Aymanns C, Keller F, Maus S, et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5:314–27. https://doi.org/10.2215/CJN.03960609.
Azab M, Doo L, Elmofti Y, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017;11:781–8. https://doi.org/10.5009/gnl16568.
Balzer KM. Drug-induced dysphagia. Int J MS Care. 2000;2:40–50.
Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–98.
Bemben NM. Deprescribing: an application to medication management in older adults. Pharmacotherapy. 2016;36:774–80.https://doi.org/10.1002/phar.1776.
Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–21.https://doi.org/10.1067/mcp.2002.121829.
Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–38.
Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33(8):902–10.
Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endosc. 1998;47(6):547–50.
Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(s1):S5.
Brown J, Brandl K, Wess J. Muscarinic receptor agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 13th ed. 2018. New York: McGraw-Hill.
Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn’s disease. Curr Gastroenterol Rep. 2011;3:465–74.
Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool and practical management tips. CPJ/RPC. 2011;144:21–34.
Buxton IO. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 13th ed. 2018. New York: McGraw-Hill. http://accessmedicine.mhmedical.com/content.aspx?bookid=2189§ionid=166182905. Accessed 11 Jan 2019.
Canadian Deprescribing Network. https://www.deprescribingnetwork.ca/professionals Accessed 11 Jan 2019.
Carabotti M, Annibale B. Treatment of diverticular disease: an update on latest evidence and clinical implications. Drugs Context. 2018;7:212526.
Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173–84.
Chetty M, Johnson TN, Polak S, Salem F, Doki K, Rostami-Hodjegan A. Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Adv Drug Deliv Rev. 2018;135:85–96. https://doi.org/10.1016/j.addr.2018.08.013.
Chien JY, Ho RJY. Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2011;100:53–8. https://doi.org/10.1002/jps.22253.
Choosing Wisely. An initiative of the ABIM Foundation. Clinician lists. http://www.choosingwisely.org/clinician-lists/. Accessed 11 Jan 2019.
Comparato G, Pilotto A, Franze A, Franceschi M, Di Mario F. Diverticular disease in the elderly. Dig Dis. 2007;25(2):151–9.
Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.
Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2:274–302. https://doi.org/10.1016/j.amjopharm2004.12.005.
De Giorgio R, Ruggeri E, Stanghellini V, et al. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastr. 2015;15:1–13. https://doi.org/10.1186/s12876-015-0366-3
Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15.
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200. https://doi.org/10.1111/j.1572-0241.2005.41217.x.
Dharmarajan TS, Yoo J, Russell RO, Norkus EP. Chronic kidney disease staging in nursing home and community older adults: does the choice of Cockcroft-Gault, modification of diet in renal disease or the chronic kidney disease epidemiology collaboration initiative equations matter? J Am Med Dir Assoc. 2012;13:151–5.
Dharmarajan TS, Choi H, Hossain N, et al. Deprescribing as a Clinical Improvement Focus [published online ahead of print, 2019 Oct 28]. J Am Med Dir Assoc. 2019;S1525-8610(19)30648-6. https://doi.org/10.1016/j.jamda.2019.08.031
Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging (BLSA): impact on renal drug dosing. Pharmacotherapy. 2013;33:912–21. https://doi.org/10.1002/phar.1282.
Edwards LL, Pfeiffer F, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord. 1991;6(2):151–6.
Elisei W, Tursi A. Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis. Ann Gastroenterol. 2016;29(1):24–32.
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.
Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician. 2015;91:293–6.
Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother. 2010;8(6):514–50.
Floch MH, White JA. Management of diverticular disease is changing. World J Gastroenterol. 2006;12(20):3225–8.
Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–9.
Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313–5.
Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361–2.
Gallagher P, Ryan C, Byrne S, et al. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.
Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic constipation in the elderly. Am J Gastroenterol. 2012;107(1):18–25.
Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14(8):846–52.
Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011;7:267–86. https://doi.org/10.1517/17425255.2011.553189.
Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.
Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974–80.
Jacobs DO. Diverticulitis. N Engl J Med. 2007;357(20):2057–66.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–61.
Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–7.
John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of inflammatory bowel disease in the elderly. Curr Treat Options Gastroenterol. 2016;14:285–304.
Juneja M, Maidoo L, Schwartz MB, Barrie A 3rd, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.
Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008;14(Suppl 2):S9–11.
Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73.
Kikendall JW. Pill-induced esophagitis. Gastroenterol Hepatol. 2007;3:275–6.
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76. https://doi.org/10.1080/03602530902722679.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.
Lakshmi Prasanna PJ, Deepthi B, Rama Rao N. Rectal drug delivery: a promising route for enhancing drug absorption. Asian J Res Pharm Sci. 2012;2:143–9.
Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30:1–9. https://doi.org/10.1093/dote/dow020.
Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886–95.
Liang X, Giacomini KM. Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci. 2017;106:2245–50. https://doi.org/10.1016/j.xphs.2017.04.078.
Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.
Lobaton Ortega T, Vermeire S, Ballet V, et al. Elderly patients with inflammatory bowel disease under anti-TNF therapy: efficacy and safety. J Crohns Colitis. 2014;8(Suppl 1):S273.
Loftus EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–8.
Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.
MacIsaac RJ, Ekinci EI, Premaratne E, al e. The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of glomerular filtration rate (GFR) in people with diabetes and preserved renal function. BMC Nephrol. 2015;16:198–211. https://doi.org/10.1186/s12882-015-0196-0.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x.
Masnoon N, Shakib S, Kalisch-Ellett CGE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230–40. https://doi.org/10.1186/s12877-017-0621-2.
McLachlin AJ, Pont LG. Drug metabolism in older people – a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67A:175–80. https://doi.org/10.1093/gerona/glr118.
Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther. 2007;26(1):9–20.
Miller JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. Adv Nutr. 2018;9:511S–8S. https://doi.org/10.1093/advances/nmy023.
Mungan Z, Simsek BP. Which drugs are risk factors for the development of gastroesophageal reflux disease? Turk J Gastroenterol. 2017;28(S 1):S39–43. https://doi.org/10.5152/tjg.2017.11.
National Institute of Diabetes and Digestive and Kidney Diseases. Estimating glomerular flitration rate. https://www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate/estimating#the-mdrd-equation. Accessed 11 Jan 2019.
National Kidney Foundation. CKD-EPI Creatinine equation. 2009. https://www.kidney.org/content/ckd-epi-creatinine-equation-2009. Accessed 3 Oct 2019.
Nyberg C, Hendel J, Nielsen OH. The safety of osmotically acting cathartics in colonic cleansing. Nat Rev Gastroenterol Hepatol. 2010;7(10):557–64.
O’Mahoney D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8. https://doi.org/10.1093/ageing/afu145.
Painter NS, Burkitt DP. Diverticular disease of the colon: a deficiency disease of Western civilization. BMJ. 1971;ii:450–4.
Painter NS, Burkitt DP. Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol. 1975;4:3–21.
Paré P, Fedorak RN. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Can J Gastroenterol Hepatol. 2014;28(10):549–57.
Poh CH, Navarro-Rodriguez T, Fass R. Review: treatment of gastroesophageal reflux disease in the elderly. Am J Med. 2010;123:496–501. https://doi.org/10.1016/j.amjmed.2009.07.036.
Raman M, Middleton RJ, Kalra PA, Green D. Estimating renal function in old people: an in-depth review. Int Urol Nephrol. 2017;49:1979–88. https://doi.org/10.1007/s11255-017-1682-z.
Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100(4):936–71.
Rao SS, Quigley EM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2014;12:616–23.
Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.
Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science. 1983;220:325–7.
Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65–77.
Schuster BG, Kosar L, Kamrul R. Constipation in older adults: stepwise approach to keep things moving. Can Fam Physician. 2015;61(2):152–8.
Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medictions in older populations: a 10-step conceptual framework. Am J Med. 2012;125:529–37.
Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9:98–112. https://doi.org/10.1177/1756283X15618131.
Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5(4):1417–35.
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–75.
Spence MM, Karim FA, Lee EA, Hui RL, Gibbs NE. Risk of injury in older adults using gastrointestinal antispasmodic and anticholinergic medications. J Am Geriatr Soc. 2015;63(6):1197–202.
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimized? Lancet. 2007;370:173–84. https://doi.org/10.1016/S0140-6736(07)61091-5.
Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193–209.
Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30(1):60–5.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40(4):312–6.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Color Dis. 2007;22(9):1103–8.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepato-Gastroenterology. 2008;55(84):916–20.
Tursi A, Papa A, Danese S. The pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment Pharmacol Ther. 2015;42(6):664–84.
U.S. Department of Health and Human Services; U.S. Department of Agriculture; U.S. Dietary Guidelines Advisory Committee. Dietary guidelines for Americans, 2010. 7th ed. Washington, DC: U.S. Government Printing Office; 2010.
Ünlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. Int J Color Dis. 2012;27(4):419–27.
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–8.
Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–83.
Won CS, Oberlies NH, Paine MF. Influence of dietary substances on intestinal drug metabolism and transport. Curr Drug Metab. 2010;11:778–92.
Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther. 2017;34(2):542–59.
Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794–800. https://doi.org/10.1097/MEG.0b013e328348a56a.
Yeung S, Traini D, Lewis D, Young PM. Dosing challenges in respiratory therapies. Int J Pharm. 2018;548:659–71. https://doi.org/10.1016/j.ijpharm.2018.07.007.
Yu C, Giuffre B. Achilles tendinopathy after treatment with fluoroquinolone. Australas Radiol. 2005;49:407–10.
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH. Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci. 2017;2312–25. https://doi.org/10.1016/j.xphs.2017.04.004
Zografos GN, Deorgiadou D, Thomas D, Kaltsas G. Drug-induced esophagitis. Dis Esophagus. 2009;22:633–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Hutchison, L.C. (2021). Pharmacology of Aging. In: Pitchumoni, C.S., Dharmarajan, T. (eds) Geriatric Gastroenterology. Springer, Cham. https://doi.org/10.1007/978-3-030-30192-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-30192-7_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30191-0
Online ISBN: 978-3-030-30192-7
eBook Packages: MedicineReference Module Medicine